BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21658248)

  • 21. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility of Staphylococcus aureus isolated from blood to currently used antistaphylococcal drugs.
    Baiocchi P; Galiè M; Santini C; Carfagna P; Cassone M; Tarasi D; Venditti M
    J Chemother; 1998 Feb; 10(1):25-8. PubMed ID: 9531072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of
    Hess KA; Kooda K; Shirley JD; Schuetz AN; Abu Saleh O; Stevens RW
    Antimicrob Agents Chemother; 2023 Jun; 67(10):e0043723. PubMed ID: 37341623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic regimen including linezolid for treating prosthetic valve endocarditis with cerebral embolism due to methicillin-susceptible Staphylococcus aureus after failure with oxacillin and teicoplanin.
    Brugraro P; Eseme F; Morelli E; Fiscon M; Rosini G; Belussi F; Ebo F; Petrucci A; Tenderini P; Raise E
    Infez Med; 2009 Dec; 17(4):240-3. PubMed ID: 20046105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.
    Pericàs JM; Messina JA; Garcia-de-la-Mària C; Park L; Sharma-Kuinkel BK; Marco F; Wray D; Kanafani ZA; Carugati M; Durante-Mangoni E; Tattevin P; Chu VH; Moreno A; Fowler VG; Miró JM;
    Clin Microbiol Infect; 2017 Aug; 23(8):544-549. PubMed ID: 28159672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics.
    Fox PM; Lampen RJ; Stumpf KS; Archer GL; Climo MW
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2951-6. PubMed ID: 16940087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.
    Jones RN; Barry AL; Gardiner RV; Packer RR
    Diagn Microbiol Infect Dis; 1989; 12(5):385-94. PubMed ID: 2533050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of oxacillin versus that of vancomycin against oxacillin-susceptible mecA-positive Staphylococcus aureus clinical isolates evaluated by population analyses, time-kill assays, and a murine thigh infection model.
    Labrou M; Michail G; Ntokou E; Pittaras TE; Pournaras S; Tsakris A
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3388-91. PubMed ID: 22430957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections.
    Klastersky J; Van der Auwera P
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():19-24. PubMed ID: 2940212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.
    Vas KE; Török Á; Cordoş B; Vancea S; Brassai A; Székely E
    J Chemother; 2016 Oct; 28(5):446-9. PubMed ID: 25976829
    [No Abstract]   [Full Text] [Related]  

  • 33. [Drug-resistance of staphylococcus aureus and detection of mecA gene in all strains isolated from children in Hangzhou].
    Hua CZ; Li JP; Yu HM; Li S; Ye H; Shang SQ
    Zhonghua Er Ke Za Zhi; 2006 May; 44(5):360-3. PubMed ID: 16780714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of teicoplanin in localized experimental infections in rats.
    Arioli V; Berti M; Candiani G
    J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Reddy VN; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2081-5. PubMed ID: 1963526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH; Hsu RB
    Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiologic characteristics and in vitro susceptibility to antimicrobials in a large population of patients with cardiovascular implantable electronic device infection.
    Jan E; Camou F; Texier-Maugein J; Whinnett Z; Caubet O; Ploux S; Pellegrin JL; Ritter P; Metayer PL; Roudaut R; Haissaguerre M; Bordachar P
    J Cardiovasc Electrophysiol; 2012 Apr; 23(4):375-81. PubMed ID: 22082221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycopeptide tolerance in Staphylococcus aureus.
    May J; Shannon K; King A; French G
    J Antimicrob Chemother; 1998 Aug; 42(2):189-97. PubMed ID: 9738836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.
    Hidalgo-Tenorio C; Gálvez J; Martínez-Marcos FJ; Plata-Ciezar A; De La Torre-Lima J; López-Cortés LE; Noureddine M; Reguera JM; Vinuesa D; García MV; Ojeda G; Luque R; Lomas JM; Lepe JA; de Alarcón A
    BMC Infect Dis; 2020 Feb; 20(1):160. PubMed ID: 32085732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.